Literature DB >> 10091994

Development of porcine adenovirus-3 as an expression vector.

P S Reddy, N Idamakanti, B H Hyun, S K Tikoo, L A Babiuk.   

Abstract

Porcine adenovirus-3 (PAV-3) was developed as an expression vector using homologous recombination in Escherichia coli BJ 5183. As a prerequisite, the complete genome of PAV-3 was first introduced as a PacI restriction fragment into a bacterial plasmid. The plasmid, when PacI restricted and transfected into swine testicular cells, produces an infectious virus. The potential of this procedure was demonstrated by the construction of several PAV-3 recombinants. Part of the E3 region, which is nonessential for virus replication under cell culture conditions, was identified and deleted from the virus genome. The gene for glycoprotein D (gD) of pseudorabies virus (PRV), which elicits PRV-neutralizing antibodies in pigs, was cloned and expressed from the E3 region of PAV-3. A 50 kDa polypeptide was identified in recombinant PAV-3-infected cell lysates by immunoprecipitation assays using gD-specific monoclonal antibodies. In another experiment, a region between the right inverted terminal repeat and the promoter of the E4 region was used to clone and express the chloramphenicol acetyltransferase (CAT) gene under the control of SV40 immediate early promoter. CAT gene expression was observed irrespective of the orientation of the CAT gene. These results indicate that the helper-independent recombinant PAV-3 could be used as an expression vector and has potential as a recombinant vaccine vector in pigs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091994     DOI: 10.1099/0022-1317-80-3-563

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

Review 1.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 2.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

3.  Porcine Adenovirus Type 3 E3 Encodes a Structural Protein Essential for Capsid Stability and Production of Infectious Progeny Virions.

Authors:  Abdelrahman Said; Tekeleselassie A Woldemariam; Suresh K Tikoo
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

4.  Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.

Authors:  Masahiko Hashimoto; Julie L Boyer; Neil R Hackett; James M Wilson; Ronald G Crystal
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3.

Authors:  Dinesh S Bangari; Anurag Sharma; Suresh K Mittal
Journal:  Biochem Biophys Res Commun       Date:  2005-06-17       Impact factor: 3.575

Review 6.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

7.  Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

Authors:  Anja Krause; Wen Zhu Whu; Yaqin Xu; Ju Joh; Ronald G Crystal; Stefan Worgall
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

8.  Construction of avian adenovirus CELO recombinants in cosmids.

Authors:  A François; N Eterradossi; B Delmas; V Payet; P Langlois
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Detection of bovine and porcine adenoviruses for tracing the source of fecal contamination.

Authors:  Carlos Maluquer de Motes; Pilar Clemente-Casares; Ayalkibet Hundesa; Margarita Martín; Rosina Girones
Journal:  Appl Environ Microbiol       Date:  2004-03       Impact factor: 4.792

Review 10.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.